Immuno 2025

12 - 14 March 2025 | London, UK

A two-day event packed with leading speakers, research and cutting-edge presentations on the latest advancements in the discovery & development of cancer immunotherapies.

Event Page - Hero Banner 5

Explore Immuno 2025: Unlocking Future Insights in Immuno Research

Join 400+ leaders, experts and researchers at Immuno 2025, connecting pharmaceutical & biotech representatives as well as academia for high-level discussions on the latest innovations in immune-oncology discovery & therapeutics development. Immuno 2025 features our ever popular 10th Annual Advances in Immuno-Oncology Congress is attended by over 400 senior level attendees in London to network, debate and discuss the industry’s pressing challenges & opportunities; fostering partnerships & collaborations in the field. Do not miss out on attending these events to stay at the forefront of the latest advancements pushing the immune-oncology industry forward – from the discovery & development of cell & gene, antibody & combination therapies, through to the utilisation of omics techniques and technologies in IO as well as novel target identification & validation strategies. New to the agenda is the introduction of the Innovation & Collaboration track showcasing emerging biotechs & pioneering academic spin off entering the market.

Immuno 2025

  • Gain a forward-looking perspective on the opportunities and challenges impacting market growth in immuno-oncology. Our congress brings together immuno-oncology experts across five tracks to provide a comprehensive look at the key trends in this industry, from therapeutic strategies and modelling through to the latest clinical data.
  • Discuss the latest innovations in novel targets & target validation in immuno-oncology. Presentations will delve into AI-based approaches for target identification & validation; new technological approaches such as screening and CRISPR and new modalities approaches.
  • Examine the latest challenges and technological innovations in preclinical development with discussions on animal modelling techniques and screening strategies along with key, preclinical considerations to drive successful entry into the clinical phase. 

Agenda at a Glance

10th Annual Advances in Immuno-Oncology Congress

  • Day One | Track 1: Immunotherapy Strategies 
  • Day One | Track 2: Microbiome & the Gut-Immune Axis
  • Day One | Track 3: Discovery & Development: Cell & Gene and Combination Therapies 
  • Day One | Track 4: Biomarkers, Precision Medicine & Multi-Omics In Immuno-Oncology
  • Day One | Track 5: IO Clinical Trials: Design, Data-Management & Case Studies
  • Day Two | Track 1: New Clinical Development for Immunotherapies
  • Day Two | Track 2: Manufacturing Novel Products at Scale
  • Day Two | Track 3: Discovery & Development: Antibody Therapies
  • Day Two | Track 4: Predictive Models & Tools for Preclinical Evaluation and Translational Development 
  • Day Two | Track 5: Novel Targets in Immuno-oncology: Identification, Validation & Exploration 

What to Expect


leading pharma, biotech & academic delegates

hours of presentations, discussions & interactive content
hours of networking breaks, including speed networking & refreshments
hours of pre-arranged 1-2-1 meetings, facilitating business growth
Interactive Presentations
Exhibition Hall
Networking Drinks
Poster Display
Event App Swapcard

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of experiences

  • Engaging Thought Leadership

    Over 80 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
  • Global Technological Showcase

    An international exhibition showcasing cutting-edge technologies and services from leading providers in the scientific field.
  • Networking Emphasis

    Unparalleled networking opportunities, including speed networking sessions, a vibrant drinks reception, and informal gatherings to foster meaningful connections
  • Innovative Poster Displays

    Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and academic institutions

Companies Represented Include

Meet Our Expert Speakers

The event brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and industry outlooks. Below were some of the featured speakers at Immuno 2024: 25 - 26 April 2024, London, UK

Eleni Chantzoura
Director of Discovery,
MiNK Therapeutics
Mani Mudaliar
Target Analyst Director,
Miguel Gaspar
Sari Pesonen
Chief Scientific Officer,
Valo Therapeutics
Xi Zhao
Senior Principal Scientist,
Alastair Corbin
Principal Scientist,
Pathios Therapeutics
Alexandra Sevko
Director, Translational Research,
Amit Grover
Associate Principal Scientist,
Angelica Loskog
Chief Executive Officer,
Lokon Pharma AB
Benoit Van den Eynde
Ludwig Institute for Cancer Research, Oxford University / VOLT
Chris Holland
Senior Manager,
Christine Rothe
Chief Development Officer,
iOmx Therapeutics
Cynthia Chauvin-Fleurence
Associate Principal Scientist,
Deepak Bhere
Assistant Professor,
University of South Carolina School of Medicine
Principal Scientist, Translational Medicine,
Eric O'Neill
Professor of Cell & Molecular Biology,
Centre for Medicines Discovery
Gray Kueberuwa
Director of Pre-Clinical Safety Research,
Instil Bio
Ida Uddbäck
Senior Scientist,
Alligator Bioscience AB
Jens Vindahl Kringelum
Vice President,
Evaxion Biotech
Johan Pijnenborg
Chief Executive Officer,
GlycoTherapeutics B.V.
John Maher
Chief Scientific Officer,
Leucid Bio
John Bridgeman
Research Director,
Instil Bio
Jon Moore
Chief Scientific Officer,
Epitopea Limited
Jonathan Kwok
Chief Executive Officer,
Kenneth Crook
Head of Translational Medicine,
Engimmune Therapeutics
Kieran Whelton
Data Scientist,
Klaus Okkenhaug
Professor of Immunology,
University of Cambridge
Livija Deban
Chief Scientific Officer,
Maria Amann
Principal Scientist,
China Innovation Center of Roche
María Laura Garcia Bermejo
Scientific Director,
Ramon y Cajal Health Research Institute (IRYCIS)
Maria Stella Sasso
Senior Principal Scientist,
Akamis Bio Ltd
Mark Cragg
Professor of Experimental Cancer Biology,
University of Southampton
Martin Miller
Senior Director,
Massimiliano Mellone
Senior Research,
Natalia Venetz
Senior Scientist,
Molecular Partners AG
Nisit Khandelwal
Founder and Former Chief Technology Officer,
iOmx Therapeutics
Øystein Rekdal
Chief Executive Officer,
Lytix Biopharma
Pedro Correa de Sampaio
Chief Executive Officer,
Phil Brailey
Crescendo Biologics
Philip Arlen
Chief Executive Officer,
Precision Biologics
Philip Beer
Chief Scientific Officer,
Step Pharma
Pierre Dönnes
Vice President,
Strike Pharma
Rahul Roychoudhuri
University of Cambridge
Raj Mehta
Chief Executive Officer,
Adendra Therapeutics Ltd
Rick Kamps
NGS Lab Manager,
University of Maastricht Translational Genomics
Robyn Broad
Principal Scientist,
Russell LaMontagne
Chief Executive Officer,
Boston Immune Technologies and Therapeutics, Inc.
Sarah-Kim Friedrich-Becker
Senior Principal Scientist,
Abalos Therapeutics GmbH
Simon Barry
Executive Director,
Sophia Karagiannis
Professor of Translational Cancer Immunology and Immunotherapy,
King's College London
Steve Thorne
Sylwia Marshall
Vice President Translational Sciences,
InvoX Pharma
Thorsten Ross
Vice President,
CatalYm GmbH
Timo Van den Berg
Senior Director Immuno-Oncology,
William Jackson
Senior Scientist,
Bioarchitech Ltd
Yi-Ru Yu
Senior Scientist,
Yong-Jie Lu
Professor in Molecular Oncology,
Queen Mary University of London

Interested in Sponsoring?

Oxford Global’s range of sponsorship opportunities are highly effective in enabling market immersion and visibility, with direct access to clients and potential customers.

Learn more

Latest Resources

First Patient Dosed with NK Cell Therapy for the Treatment of an Autoimmune Disease, Lupus Nephritis

The NK cell therapy is being trialled in combination with monoclonal antibody therapy and hopes to induce B-cell depletion.

Positive Results from iNKT Cell Therapy Clinical Trial for COVID-19 ARDS

The small exploratory trial shows signs that iNKT cells can improve the survival rate of respiratory distress from COVID-19.

Bispecific T Cell Engagers and Synthetic Immunity: Circumventing Immune Escape

Synthetic immunity mediated by bispecific T Cell engagers may help to bypass immune escape posed by a lack of appropriate immunotherapeutic target expression. Bispecific T Cell engagers offer a solution to the issue of immune escape in cancer treatments, with the potential to become off-the-shelf therapeutics.

NHS Cancer Vaccine Launchpad to Give Thousands Access to Personalised Cancer Vaccines

NHS England aims to match up to 10,000 cancer patients to suitable personalised cancer vaccine clinical trials by 2030.

AI-Enabled Predictive Biomarker for Patient Response to Immunotherapy Using Easy-to-Measure Features

The predictive biomarker does not require multi-omic or screening data, but rather routine clinical features.

H5N1 Bird Flu Outbreaks: Effect on Vaccines

H5N1 outbreaks in the US have mobilised pandemic preparedness mechanisms with stockpiling of avian flu vaccines.

Plan Your Visit

Wednesday 24th April 2024 – £192 including VAT and breakfast - SOLD OUT

Thursday 25th April 2024 – £192 including VAT and breakfast - SOLD OUT 

*Please note: £10 supplement is applicable for double occupancy


We have now sold out of our discounted bedrooms. You can book your nights directly through the hotel's website linked here

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Immuno 2025 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

Register Your Interest

Submit your details and a member of our team will be in touch